Wound closure in epidermolysis bullosa: data from the vehicle arm of the phase 3 ESSENCE Study

  • Dedee Murrell (Contributor)
  • Amy Paller (Creator)
  • Christine Bodemer (Creator)
  • John C. Browning (Creator)
  • Milos Nikolic (Contributor)
  • Jay Barth (Creator)
  • Hjalmar Lagast (Creator)
  • Eva Krusinska (Creator)
  • Allen Reha (Creator)



Abstract Background Chronic wounds are a fundamental issue for patients with epidermolysis bullosa (EB). Herein, we assess the natural history of wound closure in patients with EB who were randomly assigned to the vehicle-control arm of the multicenter, randomized, double-blind, phase 3 ESSENCE (NCT02384460) trial. Methods ESSENCE was designed to assess the efficacy and safety of a topical cream formulation of 6% allantoin (SD-101 6%) vs vehicle (SD-101 0%) in patients ≥1 month old who had a diagnosis of EB (simplex, recessive dystrophic, or intermediate junctional) and a target wound 10–50 cm2 present for ≥21 days. Time to complete target wound closure and the proportion of patients with target wound closure over time were analyzed overall and by parameters including patient age and baseline body surface area index (BSAi) of total wound burden (
Date made available2020

Cite this